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a b s t r a c t
miRNAs regulate gene expression by binding to cognate mRNAs causing mRNA degradation
or translational repression. Mass spectrometry-based proteomic analysis is being widely
used to identify miRNA targets. The miR-200b miRNA cluster is often overexpressed in
multiple cancer types, but the identity of the targets remains elusive. Using SILAC-based
analysis, we examined the effects of overexpression of amiR-200bmimic or a controlmiRNA
in ﬁbrosarcoma cells. We identiﬁed around 300 potential targets of miR-200b based on aKeywords:
Mass spectrometry
miRNA targets
HT-1080
change in the expression of protein levels. We validated a subset of potential targets at the
transcript level using quantitative PCR.
© 2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
further processed to produce ∼22 nucleotide long mature
1. IntroductionMicroRNAs (miRNA) are 21–25 nucleotides long non-coding
RNAs that pair with mRNAs to regulate gene expression.
Genes that encode miRNAs are transcribed to produce long
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article under the CC BY-NC-ND license (http://creativecommons.org/lichairpin pri-miRNAs (primary transcripts). These pri-miRNAs
are processed by drosha to produce pre-miRNAs, which arebioinformatics.org (A. Chatterjee).
miRNAs. The complementarity of seed sequence (six or
seven nucleotides at 5′ end of mature miRNA) to the tar-
get mRNA determines the mode of gene regulation. Perfect
European Proteomics Association (EuPA). This is an open access
enses/by-nc-nd/3.0/).
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omplementarity results in degradation of target mRNA and
mperfect complementarity leads to translational repression
f the target transcript [1].
miRNAs are known to bind multiple targets and have been
hown to regulate various biological process including devel-
pment [2], differentiation [3], apoptosis and organogenesis
4,5]. Though thousands of miRNAs have been discovered,
heir function is yet to be clearly deﬁned. In cancer, miR-
As have been shown to function both as oncogenes and
umor-suppressors [6]. miR-200b belongs to miR-200 family
f miRNAs, which includes miR-200a, miR-200c, miR-429 and
iR-141. The miR-200 family is implicated in negative regula-
ion of epithelial tomesenchymal transition [7,8]. For example,
iR-200b was found to be deregulated in neuroblastoma [9],
erous ovarian carcinoma [10] and colorectal carcinoma [11].
u et al. have shown the prognostic value of miR-200b in
varian cancers [12]. Aberrant expression of miR-200b is also
nown to enhance tumor growth [12]. Despite these stud-
es the mechanisms by which miR-200b exerts its function
emains unclear. Also, the number of identiﬁed miR-200b tar-
ets remain relatively limited thus precluding a complete
nderstanding of the full oncogenic/tumor suppressor poten-
ial of this miRNA.
It is known thatmiRNA regulation at the translational level
s more pronounced than the transcriptional level [13]. Hence
his study is focused on identiﬁcation of targets at the protein
evel using SILAC (stable isotope labeling by amino acids in
ell culture)-based quantitative proteomic methodology [14].
ILAC is an unbiased method to identify differential protein
xpression. It exploits theuse of different stable isotopic forms
f amino acids, so that chemical nature of the medium across
onditions remains the same except for subtle variations in
he mass of stable isotopic amino acids used, which can be
ifferentiated in the mass spectrometer. One of the major
dvantages of SILAC is that multiplexing occurs at the protein
evel reducing experimental errors in downstreamprocessing.
hismethod has been successfully used in previous studies to
dentify miRNA targets [15,16]. By this approach, we analyzed
he expression proﬁle of proteins in ﬁbrosarcoma cells upon
orced expression of miR-200b. Fibrosarcoma cell line HT-1080
s an excellent model to study the effects of miR-200b as this
ell line exhibits high levels of ZEB1which is a proven target of
iR-200 cluster. Our results indicate that HT-1080 expresses
ow to undetectable levels of miR-200b, which is in agreement
ith previous report by Hurteau et al. [17].
Our results indicate that miR-200b regulates multiple
roteins involved in tumor progression including cell cycle
rogression and cell proliferation. Most importantly, we iden-
iﬁed 300 differentially expressed proteins as potential targets
f miR-200b.
. Materials and methods
.1. Cell culture, miRNA treatmentuman ﬁbrosarcoma cells (HT-1080) were grown in DMEM
edium. The cells were either grown in regular DMEM media
r SILAC media containing heavy isotopes of Arg (13C6) and
ys (1H4). The cells grown in normal media were mock4 ( 2 0 1 4 ) 10–17 11
transfected with 100nm of miRIDIAN microRNA mimic, nega-
tive control (Dharmacon) and the cells grown in SILAC media
were transfected with 100nm miR-200b mimic (miRIDIAN
hsa-miR-200b mimic, Dharmacon). The cells were lysed 48h
post-transfection inurea lysis buffer (9Murea in 20mMHEPES,
pH 8). Protein estimation was carried out using Lowry’s assay.
The samples were pooled after normalization. Strong-cation
exchange chromatography (SCX) was carried out as described
earlier [18]. Brieﬂy, dithiothreitol (5mM) was used to reduce
the pooled proteins followed by addition of 10mM iodoac-
etamide resulting in alkylation. Protein digestion was carried
out using Trypsin (modiﬁed sequencing grade; Promega,Madi-
son, WI) for 16h at 37◦. Polysulfoethyl A column (PolyLC,
Columbia, MD) (100×2.1mm, 5m particles with 300 A˚ pores)
was used for fractionation of digested peptides. Twenty ﬁve
SCX fractions (0.5mL)were collected froma 0–350mMKCl gra-
dient in the presence of 10mM potassium phosphate buffer
(pH 2.85), containing 25% acetonitrile for 70min at a ﬂow rate
of 0.2mL/min. Solvent A contained 10mM potassium phos-
phate buffer, pH 2.85, 25% acetonitrile and solvent B contained
10mM potassium phosphate buffer, 350mM KCl, pH 2.85, 25%
acetonitrile. The Desalting was done using C18-stagetips. The
cleaned fractions were dried and stored at −80 ◦C until mass
spectrometry analysis.
2.2. LC–MS/MS analysis
The peptides from SCX fractions were reconstituted in 0.1%
formic acid and analyzed using the 6520 Accurate-Mass Q-
TOF mass spectrometer (Agilent Technologies, Santa Clara,
CA, USA) interfaced with nanoﬂow HPLC-Chip Cube system
(Agilent Technologies, Santa Clara, CA, USA). The HPLC-Chip
contains columns made up of a reversed-phase material
Zorbax 300SB-C18, particle size of 5m. The high capacity
enrichment column (160nl) was used whereas 15 cm analyti-
cal column was utilized for peptide separation. The samples
were loaded on an trap column using Agilent 1200 series HPLC
system at a ﬂow rate of 4l/min using solvent A (0.1% formic
acid). The peptides were eluted at the ﬂow rate of 400nl/min
using a gradient of 3–40% Solvent B (90% acetonitrile in 0.1%
formic acid). MS data was acquired using MassHunter Data
Acquisition software (Version B.01.03, Agilent Technologies,
Santa Clara, CA, USA). MS spectra were acquired in the range
of m/z 350–1.800 followed by maximum of three MS/MS anal-
yses with the scan range of m/z 50–2000. The duty cycle was
set to 2.1 s with 1MS scan per second followed by 3MS/MS
scans per second. The precursor selection was based on pref-
erence to charge state in the order of 2+, 3+ and >3+ ions and a
second level preference to abundance. The mass spectrome-
ter was operated at capillary voltage of 1950V and fragmentor
voltage of 175V. Peptide isolation was set to medium (4 m/z)
and collision energy slope of 3V plus offset of 2V.
2.3. Data analysis
The raw mass spectrometry data was searched using Spec-
trum Mill proteomics workbench software (Rev. A.03.03,
Agilent Technologies). The raw data was searched against
Human RefSeq database (Build 47; 34,906 sequences) using
Spectrum Mill algorithm. Trypsin was selected as protease
12 e u pa open proteomics 4 ( 2 0 1 4 ) 10–17
R
el
at
iv
e 
ex
pr
es
si
on
 u
ni
ts
HT-1080
MCF7
MDAMB231
MDAMB468
ZR751
0.001
0.01
0.1
1
10
100
1000
10000
Fig. 1 – Endogenous expression of miR-200b in HT-1080. Endogenous expression of miR-200b in HT-1080 as compared to
other cell lines as determined by quantitative PCR (TaqMan MicroRNA assay for miR-200b). Among the cell lines tested,
HT-1080 shows the lowest expression of miR-200b.
with maximum one missed cleavage allowed. Oxidation of
methionine, 13C6 arginine and D4 lysine were selected as
variable modiﬁcations while carbamidomethylation of cys-
teine was selected as a ﬁxed modiﬁcation. MS tolerance
was set to 20ppm while MS/MS tolerance was set to 0.8Da.
False discovery rate (FDR) was estimated based on decoy
database searches. Applying FDR cut-off of 1%, 3751 unique
peptide spectralmatcheswere obtained corresponding to 1975
non-redundant peptides. The peptides were then grouped to
proteins using default parameters provided in the Spectrum
Mill search engine (protein score>11, % SPI > 60). The “DEQ
ratios” ﬁeld was checked in the Spectrum Mill to compute
relative quantitation of proteins.
2.4. Experimental validation of the identiﬁed targets
2.4.1. qPCR validation
Endogenous expression of miR-200b in different cell lines
was determined by performing real time PCR using TaqMan®
MicroRNA Reverse Transcription Kit, TaqMan Universal PCR
Master Mix and TaqMan MicroRNA Assay (Applied Biosys-
tems, Foster City, CA). CT value of miR-200b was normalized
to the CT value of U6B (a small RNA) in the same sample.
The expression levels of potential miR-200b target genes were
measured using SYBR Green PCR System (TaqMan) as pre-
viously described [13]. Brieﬂy, total RNA was extracted from
the transfected cells using miRNeasy kit (Qiagen) according
to the manufacturer’s instructions. Reverse transcription was
performed using Quantiscript Reverse Transcription Kit (Qia-
gen). For qRT-PCR, 1l of gene primers with SYBR Green
(Applied Biosystems) in 20l of reaction volume was applied
and analyzed using Rotor-Gene Q Real time cycler (Qiagen).
The primers used in this study are provided in Supplementary
Table 3. Target gene mRNA levels were normalized to UTP14A(control) mRNA according to the following formula: [2− (CT
target−CT UTP14A)]×100%, where CT is the threshold cycle.
The relative expression was calculated by dividing the nor-
malized target gene expression of the miR-200b transfected
sample with that of the mock transfected.
Supplementary Table 3 related to this article can be found,
in the online version, at doi:10.1016/j.euprot.2014.04.006.
2.5. Data submission
We have deposited the raw mass spectrometry data (.d
ﬁles) to proteomics data repository – Tranche (https://
proteomecommons.org/tranche/). These ﬁles can be visual-
ized using Agilent MassHunter Qualitative Analysis software
(Agilent Technologies). The data can be downloaded using fol-
lowing hash:
6H4E7I0l66VE9lOUdhMXPTxKvhTFVsL64sJcfC+Xoz//
OTtebZXKVySQ9byKu+8T3sutjo0yDd2TpjFBVm2k2VmXdU
0AAAAAAAIj9Q==.
3. Results
In order to identify targets of miR-200b, we employed a quan-
titative proteomic approach using HT-1080, a ﬁbrosarcoma
cell line expressing low to undetectable levels of miR-200b
(Fig. 1). The workﬂow employed in this study has been shown
in Fig. 2. HT-1080 cells were either transfected with miR-200b
mimic or the control miRNA. The HT-1080 cells expressing
exogenous miR-200b were grown in DMEM media with heavy
arginine and lysine, the cells harboring the control miRNA
were grown and maintained in normal media. Forty eight
hours post transfection the cells were harvested. Normalized
protein amounts from the two states were mixed, followed
e u pa open proteomics
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Fig. 2 – Workﬂow employed in this study: HT-1080 cells
were either grown in normal media or adapted in SILAC
media supplemented with heavy arginine(13C6) and lysine
(D4). The cells grown in normal media were mock
transfected and the cells grown in SILAC media were
transfected with miR-200b mimic. Forty eight hours post
transfection the cells were lysed in urea buffer. The
samples were pooled after normalization and subjected to
trypsin digestion followed by fractionation using SCX
chromatography. Fractionated samples were subjected to
LC–MS/MS analysis on a Q-TOF mass spectrometer. The
raw data was searched and quantitated using Spectrum
M
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downregulation in presence ofmiR-200b. Of the 13 tested can-ill proteomics workbench.
y in-solution digestion and SCX fractionation, followed by
C/MS–MS analysis.
.1. LC–MS/MS analysis
C–MS/MS analysis of HT-1080 cells overexpressing miR-200b
ompared to the parental cell line led to the identiﬁcation of
99 proteins. The proteins were identiﬁed by searching the
pectra against human RefSeq protein database. Differential4 ( 2 0 1 4 ) 10–17 13
expression of proteins in miR-200b transfected vs control
transfected cells were quantiﬁed using Spectrum Mill. Pro-
teins with a ratio of ≥2 were considered as upregulated
and with a ratio of ≤0.5 were considered as downregulated.
Previous studies from our group as well as other miRNA
research groups have shown that global effects of miRNAs
on protein expression levels are often moderate and sub-
tle [13,19–21]. Aforementioned studies have reported that the
average change observed at protein level was between 10 and
35%. Based on these observations, a fold-change of 2 was
selected to be sufﬁciently stringent to preclude false positives
even with the known risk of losing some real candidates as
false negatives. With this criterion, 300 proteins were found to
be differentially expressed with majority of the proteins get-
ting downregulated. The complete list of identiﬁed proteins
and peptides are provided in Supplementary Tables 1 and 2,
respectively.
Supplementary Tables 1 and 2 related to this article
can be found, in the online version, at doi:10.1016/j.euprot.
2014.04.006.
3.2. Bioinformatics analysis
The potential targets of miR200b identiﬁed above were
then compared with the known predicted targets of miR-
200b using TargetScan (http://www.targetscan.org) andmiRDB
(http://www.miRdb.org). From the potential targets identiﬁed
from our study, 60 were predicted targets of miR-200b either
by TargetScan or miRDB, 19 proteins were predicted targets
by both. In addition to the above, we identiﬁed more than
200 novel targets of miR-200b which include ANXA1 (Annexin
A1), LGALS3 (Galectin 3), HMGB1 (High mobility group pro-
tein 1) and EIF5A (Eukaryotic translation initiation factor 5A-1).
MS/MS spectra of a subset of these candidates are shown in
Fig. 3 (Table 1).
3.3. Real-time PCR analysis
miRNA regulates by binding to its cognate mRNA followed
by transcriptional and/or translational repression. Next we
validated the miR200b novel targets identiﬁed in this study
at the transcript level using quantitative real-time PCR.
Thirteen of the novel potential targets including, CAST (Cal-
pastatin), LGALS3 (Galectin-3), ANXA1 (Annexin A1), HMGB1
(High mobility group protein B1), FN1 (Fibronectin 1), CDK6
(Cyclin-dependent kinase 6), EIF5A (Eukaryotic translation ini-
tiation factor 5A), PAK2 (p21activated protein kinase 2), TRAP1
(TNF-receptor associated protein 1), PRDX1 (Peroxiredoxin-1),
PDCD5 (Programmed cell death protein 5), HINT1 (Histidine
triad nucleotide-binding protein 1), CSE1L Exportin-2, (down-
regulated) were analyzed (Fig. 4). As depicted in the ﬁgure, the
blue bars represent expression of the genes at the transcript
level in cells transfected with control mimic whereas the red
bar represents the transcript levels in cells transfected with
miR-200b. Our data indicates that except for CSE1L, HMGB1
and PDCD5, the other potential targets show transcriptionaldidates, eight were in concordance with the proteomic data
(downregulated ≥1.6 fold at the mRNA level) (Supplementary
Table 4).
14 e u pa open proteomics 4 ( 2 0 1 4 ) 10–17
Fig. 3 – MS and MS/MS spectra of representative peptides of proteins. (a) Peroxiredoxin 1 (PRDX1), (b) Annexin A1 (ANXA1),
p21a(c) Eukaryotic translation initiation factor 5A (EIF5A), and (d)
Supplementary Table 4 related to this article can
be found, in the online version, at doi:10.1016/j.euprot.
2014.04.006.
4. DiscussionBoth computational prediction and experimental approaches
are commonly used to determine and predict miRNA tar-
gets. Computational algorithms such as TargetScan,miRanda,
Table 1 – A subset of novel candidate targets of miR-200b ident
Gene symbol Protein name
CAST Calpastatin
LGALS3 Galectin-3
ANXA1 Annexin A1
HMGB1 High mobility group protein B
FN1 Fibronectin 1
CDK6 Cyclin-dependent kinase 6
EIF5A Eukaryotic translation initiat
PAK2 Serine/threonine-protein kin
DNM1L Dynamin-1-like protein
TRAP1 TNF-receptor associated prot
PRDX1 Peroxiredoxin-1
PDCD5 Programmed cell death prote
HINT1 Histidine triad nucleotide-bin
CSE1L Exportin-2ctivated protein kinase 2 (PAK2).
Target boost, Pictar andPITAare broadlyused topredict targets
[22]. Experimental identiﬁcation of targets is largely driven by
transcriptomic approaches including DNAmicroarrays, quan-
titative real time PCR-based assays; pull down assays for
argonaute complexes. One of the major drawbacks of the
above mentioned methods is that they are unable to readout
the effect of miRNA on its target protein. Mass spectrometry-
based proteomics approach have been used successfully to
elucidate miRNA targets [22]. We and others have success-
fully used this platform for identiﬁcation of miRNA targets
iﬁed in this study.
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Fig. 4 – Veriﬁcation of a subset of the identiﬁed targets by qPCR analysis. Relative expression levels of a subset of target
mRNAs in mock transfected and miR-200b transfected HT-1080 cells are shown. The inset shows the expression of genes at
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13,15,19,23]. With the advent of quantitative proteomics,
iRNA targets that undergo translational repression can be
uccessfully identiﬁed which would be otherwise overlooked
n experimental approaches that measures mRNA. Different
abeling strategies including SILAC [15], iTRAQ [13], ICAT [24] –
ased proteomic approaches have been employed to discover
argets of miRNAs.
The cluster of miR-200 miRNAs have been reported to
lay a major in role in multiple cancer types [12]. Although
he tumor suppressor nature of miR-200 family of miRNAs
ave been established [25–27], the underlying targets and
ignaling cascade that are dysregulated remain undeﬁned.
iR-200b has also been shown to play a protective role in
ancer progression through negative regulation of epithelial
o mesenchymal transition [6]. Using LC–MS/MS analysis, we
ave identiﬁed more than 200 potential targets of miR-200b
hich were >2-fold downregulated. Many potential targets of
iR-200b have known association with cancer progression.
or example, overexpression of protein tyrosine phosphatase
1 (PTPN11), a tyrosine phosphatase with SH2 domain, has
een shown to be involved in breast cancer progression [28].
imilarly, overexpression of 14-3-3 gamma (YWHAG), has been
hown to promote invasion and metastasis in hepatocellular
arcinoma [29]. Mucosae associated lymphoid translocationon of CDK6, TRAP1, PAK2, CAST and LGALS3.
gene 1 (MALT1) is a known oncogene that is rearranged
in chromosomal translocation with the apoptosis inhibitor
gene API2 [30] or with microtubule-associated protein 4 MAP4
[31]. MALT-API2 gene fusion has been reported as commonly
occurring translocation inmucosa associated lymphoid tissue
lymphomas [32]. These proteins were identiﬁed as targets of
miR-200b in our study where forced overexpression of miR-
200b led to a decrease in expression of the above mentioned
proteins PTPN11, YWHAG and MALT1 by 2-fold, 2-fold and 4-
fold, respectively. Another well established oncogene whose
role has been implicated in multiple cancers is eukaryotic
translation initiation factor 5A (EIF5A). Overexpression of this
protein has been associated with poor prognosis in hepatocel-
lular carcinoma [33]. It is the only knownprotein in eukaryotes
which carries the unusual aminoacid hypusine. BCR-ABL posi-
tive cells treatedwithhypusination inhibitors (EIF5A inhibitor)
has shown antiproliferative effects in K562 cells [34] con-
ﬁrming the oncogenic activity of EIF5A. Our study indicates
EIF5A as a potential target of miR-200b as it was 4-fold down-
regulated in presence of overexpression of miR-200b. Moesin
is another known oncogene, reported in HNSCC, and a target
of miR-133a, which too is known to have a tumor suppressive
role by targeting the moesin (MSN) gene [35]. In this study we
identiﬁed moesin as a novel target of miR200b. Mosein was
omic
r16 e u pa open prote
observed to be downregulated by 2-fold in the presence of
miR-200b.
Apart from being a tumor suppressor, miR-200b also func-
tions as an oncomiR in certain cancers [36,37]. In the current
study, we could identify miR-200b target proteins which were
signiﬁcantly downregulated and has literature support of
having tumor suppressor role in multiple cancer types. Cal-
pastatin (CAST), showed 12-fold downregulation by miR-200b.
Low expression of CAST has been shown to be associatedwith
lymphovascular invasion in breast cancer [38]. High mobil-
ity group protein B1 (HMGB1) has been reported to maintain
DNA integrity by regulating DNA repair [39,40]. It has been
reported to activate apoptotic response in case of genotoxic
stress [40]. Depletion of this protein has been shown to pro-
mote carcinogenesis. In accordance with these observations
we found a 3-fold downregulation of HMGB1 in response to
exogenous expression of miR-200b in HT-1080 cells. These
studies suggest thatmiR-200bmight be involved in tumor pro-
gression. Further, evidence in support of the oncogenic role of
miR-200b comes from the involvement of programmed cell
death 5 (PDCD5) in tumorigenesis, which is downregulated
in our study. Low expression of this protein in patients with
chondrosarcoma had poor prognosis as compared to patients
with high expression. Other proteins which were downreg-
ulated in response to exogenous expression of miR-200b in
HT-1080 were HINT1 (2-fold), ANXA1 (4-fold) and LGALS3 (10-
fold). Decreased expression of these proteins has been shown
to be involved in tumor progression in different cancer types.
Histidine triad (HIT) family of proteins are small family of
nucleotide binding proteins whose expression is shown to
be lost in multiple human malignancies [41]. In hepatocel-
lular carcinoma, histidine triad nucleotide binding protein 2
(HINT2), a nuclear encoded mitochondrial protein has been
reported to be downregulated. Restoration of the expression
of this protein has been shown to induce apoptotic response
in HEPG2 cells [42]. Loss of annexin A1 expression has been
shown to inversely correlatewith the progression of oral squa-
mous cell carcinoma. Poorly differentiated carcinoma cells
have been shown to have signiﬁcantly lower expression of this
protein as compared to well differentiated cells [43]. Down-
regulation of Galectin-3 (LGALS3) has been reported in tumor
progression in cervical and prostate carcinomas [44,45]. These
studies further support the notion that miR-200b behaves as
an oncogene and plays a role in tumor progression.
In the present study using mass spectrometry-based
approach, we have identiﬁed potential targets of miRNA. Fur-
ther experiments are warranted to understand whether these
are direct or indirect target of miR-200b. This study provides
a lead for further research on identiﬁed potential targets. In
summary, we have identiﬁed 300 proteins as candidate targets
of miR-200b using a global quantitative proteomic approach.
Eight out of 13 tested targets were conﬁrmed to be regu-
lated at transcription level. Forced expression ofmiR-200b has
led to dysregulation of its targets. A handful of these targets
have been identiﬁed as oncogenes in other studies, implicat-
ing miR-200b to possess a tumor suppressor role, whereby in
the current study these targets were observed to be down-
regulated. Also, studies have indicated miR-200b to possess
oncogenic property. In concordance with such observations,
we too identiﬁed downregulated targets of miR-200b, whoses 4 ( 2 0 1 4 ) 10–17
loss or decrease in expression has been associated with can-
cer progression. In depth studies are required to elucidate the
combined role of the identiﬁed targets to further conﬁrm the
role of miR-200b in cancer progression.
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